Oxaprozin

CHEMBL1071 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

293.3 g/mol

LogP

4.2

Phase

4

A long-acting NSAID allowing once-daily dosing for arthritis pain and inflammation.

分子量

293.3000 g/mol

LogP

4.20

TPSA

63.30 Å²

リピンスキーの五則

適合

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1

InChI

InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)

Molecular Formula

C18H15NO3

HBD / HBA

1 / 4

回転可能結合数

5

重原子数

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A long-acting NSAID allowing once-daily dosing for arthritis pain and inflammation.

Yes, Oxaprozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1071. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4614. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Oxaprozin PillFYIで

構造

クイックデータ

分子式: C18H15NO3
同義語: 2

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.